Purpose: To report the clinical presentation, microbiologic spectrum, and visual outcomes associated with acute-onset infectious endophthalmitis undergoing therapeutic pars plana vitrectomy.
Purpose: To report the clinical presentation, microbiologic spectrum, and visual outcomes associated with acute-onset infectious endophthalmitis undergoing therapeutic pars plana vitrectomy.
Methods: Multicenter interventional retrospective noncomparative consecutive case series. Billing records were reviewed to identify all charts for patients undergoing pars plana vitrectomy within 14 days of diagnosis of acute-onset infectious endophthalmitis over a 4-year period at 5 large tertiary referral retina practices. Statistical analysis was performed to assess for factors associated with visual outcomes.
Results: Seventy patients were identified. The most common clinical setting was postcataract surgery (n = 20). Only 3 patients (4.3%) presented with 20/400 or better visual acuity (VA). Although most of the patients initially underwent vitreous tap and intravitreal antibiotic injection (n = 47, 67.1%), all patients eventually underwent pars plana vitrectomy within 14 days of presentation with 68.5% (48/70) of patients undergoing pars plana vitrectomy within 48 hours of presentation. Positive intraocular cultures were obtained in 56 patients (80%). The most common identified organism was Streptococcus sp (n = 19). Visual acuity at last follow-up was 20/400 or better in 19 patients (27.1%). Three patients underwent evisceration or enucleation (4.3%). Last recorded postoperative VA (mean LogMAR 1.99 ± 0.94, Snellen VA equivalent finger count) improved from presenting VA (mean LogMAR 2.37 ± 0.38, Snellen VA hand motions) (P # 0.001). There was no statistically significant correlation between the underlying etiology or the timing of surgery with this VA outcome.
Conclusion: Although less than one-third of patients achieved 20/400 or better VA, this VA often improved significantly from presenting VA.
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A cute-onset infectious endophthalmitis continues to be a significant cause of vision loss, regardless of etiology. 1 Treatment options include diagnostic vitreous tap and injection of antimicrobials or diagnostic and therapeutic pars plana vitrectomy (PPV) with injection of antimicrobials. 2 Pars plana vitrectomy for endophthalmitis, first described in the 1970s, carries the theoretical advantages of debulking the vitreous cavity of virulent organisms, removing vitreous opacities, and improving intravitreal circulation of antimicrobials. [2] [3] [4] [5] For many years, the optimal patient selection and timing for PPV in the treatment of endophthalmitis was controversial. The Endophthalmitis Vitrectomy Study (EVS), a multicenter prospective randomized controlled trial published in 1995, included 420 eyes with postcataract surgery endophthalmitis. 6 The EVS demonstrated that for eyes with better than light perception (LP) visual acuity (VA) on presentation, outcomes of PPV as initial therapy versus vitreous tap and intravitreal antibiotic injection were the same. Based on these results, the EVS recommended that PPV serve as initial therapy for those patients presenting with LP VA or worse. 1, 6 The current applicability of the EVS remains an issue, however, in determining the optimum treatment strategy for the patient with all-cause acute endophthalmitis.
To better understand the present-day outcomes of acute-onset endophthalmitis with PPV, a multicenter retrospective collaborative study was undertaken to analyze the microbiologic spectrum and VA outcomes. For statistical analysis, Snellen visual acuities were converted to the logarithm of the minimal angle of resolution (LogMAR) scale. 7 For LogMAR values worse than 1.60, the following previously used scale was applied: counting fingers (CF), 2.00; hand motion (HM), 2.30; LP, 2.60; NLP, 2.90. [8] [9] [10] Paired variables before and after surgery were analyzed using the Wilcoxon signed-rank test. Nonparametric distribution was confirmed using histogram plots. The KruskalWallis test was used to determine whether there were differences between multiple groups. All statistical tests were 2-tailed, and significance was defined as P , 0.05. Statistical analysis was performed using Stata version 9.0 (StataCorp, LP, College Station, TX).
Methods

Institutional
Results
This study included 70 patients with a mean age of 67.1 years (range 16-97). All cases were unilateral with 40 right eyes and 30 left eyes included. Mean follow-up was 12.5 months (median: 12 months, range 2 weeks-40 months). Six patients with less than 3 months of follow-up were included: 3 patients had NLP at final visit and 3 patients underwent either enucleation or evisceration.
Baseline Clinical Features and Visual Acuity
The most common clinical settings were postcataract surgery (n = 20), postintravitreal injection (n = 12), and posttrabeculectomy (n = 11) ( Table 1) . Hypopyon was present in 50 of 60 eyes (83.3%), and 69 of 70 eyes (98.6%) presented with no view of the fundus. Most of the patients were pseudophakic with a posterior chamber intraocular lens (43/70, 61.4%). Presenting visual acuities were 20/400 or better (n = 3), CF (n = 6), HM (n = 28), LP (n = 30), and NLP (n = 3). Of note, the three NLP cases included two cases of acute posttrabeculectomy endophthalmitis that underwent immediate PPV and one case involving an extruding fluocinolone intravitreal implant that necessitated immediate surgical removal simultaneous with PPV.
Treatment Strategies
Initial treatment strategies were vitreous tap and injection of antimicrobials (67.1%, n = 47) or PPV with intravitreal antimicrobials (32.9%, n = 23) ( Table 2) . Antimicrobials used included combinations of vancomycin, ceftazidime, gentamicin, amikacin, and voriconazole (in cases of suspected fungal endophthalmitis). Intravitreal corticosteroids were only used in 7 patients (10.0%). All patients eventually underwent PPV, an average of 2.0 days after initial presentation (range 0-14 days). None of the authors has any financial/conflicting interests to disclose.
Reprint requests: Sunir J. Garg, MD, Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107; e-mail: sunirgarg@gmail.com Thirty-five patients (50.0%) underwent PPV within 24 hours of presentation, 13 patients (18.6%) underwent PPV 24 to 48 hours from presentation, and 22 patients (31.4%) underwent PPV between 48 hours and 14 days after presentation. Cannula size used during PPV included 23 gauge (n = 48, 68.6%), 25 gauge (n = 20, 28.6%), and 20 gauge (n = 2, 2.9%).
Microbiologic Characteristics
Positive intraocular cultures were obtained in 56 of 70 patients (80.0%) ( Table 3) . Nearly all positive cultures were obtained from vitreous specimens (n = 52) rather than aqueous humor samples (n = 4). Vitreous specimens consisted of vitreous tap aspirates from the office (n = 29) and PPV specimens (n = 23). Patients who went directly for PPV had an undiluted vitreous specimen taken and sent for culture before opening an infusion line into the eye. In addition, PPV cassettes were sent for culture at the conclusion of surgery. The most common identified organisms were Streptococcus sp (n = 19) and coagulase-negative staphylococcus (n = 14). Of the Streptococcus cases 8 occurred after cataract surgery and 4 were associated with infected trabeculectomy blebs. Most of the Streptococcus cases were alpha-hemolytic (13/19, 68.4%). Multiple organisms were not present in any culture-positive cases. All organisms were sensitive to at least one of the initially administered antibiotics. ACIOL, anterior chamber intraocular lens; CE/IOL, cataract extraction and intraocular lens placement; DSEK, Descemet's stripping endothelial keratoplasty; GDI, glaucoma drainage implant; IOL, intraocular lens; IV, intravitreal; IVI, intravitreal injection; Kpro, keratoprosthesis; PCIOL, posterior chamber intraocular lens; PKP, penetrating keratoplasty. 
Treatment Outcomes
Visual acuity at last follow-up was 20/400 or better (n = 19), CF (n = 9), HM (n = 14), LP (n = 7), and NLP (n = 21) ( Table 4 Fifteen eyes (21.4%) were noted to have a retinal detachment either at the time of initial PPV or on follow-up. Eight eyes underwent more than one PPV and seven eyes received silicone oil tamponade. In this group, last follow-up VA ranged from CF to NLP except for one eye that ultimately underwent silicone oil removal and had final VA of 20/40 with an attached retina.
On subgroup analysis, while the presenting VA for postintravitreal injection patients was significantly better than the posttrabeculectomy patients (P = 0.025), there was no other statistically significant differences between initial, final, or change in VA among postcataract surgery, postintravitreal injection, and posttrabeculectomy patients. Similarly, there was no statistically significant difference in initial, final, or change in VA between patient groups undergoing PPV within 24 hours of presentation, between 24 and 48 hours of presentation, and more than 48 hours after presentation. There was a statistically significant improvement in VA from presentation and last follow-up visit in the 23-gauge surgery patients (initial: There was no significant difference identified in VA outcome between patients who underwent PPV within 24 hours versus PPV after 24 hours (P = 0.37), nor between patients who were postcataract surgery versus other etiologies (P = 0.44).
Discussion
The concept of using PPV in acute-onset endophthalmitis dates to the 1970s, when both small human subject case series and experimental animal model studies demonstrated potential value to early PPV. [3] [4] [5] 11 Olson et al 12 described selecting endophthalmitis cases for PPV with worse initial VA and more virulent organisms on culture. Another small series reported achieving 20/80 or better in all 5 eyes that underwent PPV within 24 hours of presentation. 13 Vitreous biopsy using the vitrectomy cutter was also noted to have the added benefit of a higher likelihood of positive culture result than a vitreous tap with a needle. 14 The EVS was the first large prospective randomized study examining the role of 20-gauge PPV in endophthalmitis, and based on its cohort of postcataract endophthalmitis cases, recommended that PPV serve as initial therapy in those patients presenting with LP VA or worse. 6 This study is different from the EVS in several ways. First, in this study, concurrent and preexisting diseases were not used for exclusion, patients presented at Mean follow-up: 12.5 months. Enuc, enucleation; Evisc, evisceration. variable times, and multiple surgeons made the decision for the use of vitrectomy. In the EVS, a total of 854 patients with clinical evidence of endophthalmitis were screened for eligibility, but only 420 participants met study criteria and agreed to randomization. 6 Reasons for exclusion included history of intraocular surgery other than cataract surgery (7.5%), history of penetrating trauma (1%), history of glaucoma (12%), history of retinal detachment (2%), and best-corrected VA 20/100 or worse before the development of cataract (5.4%). 15 Eyes with NLP VA or retinal detachment at presentation were also excluded. The strict inclusion/exclusion criteria help explain the difference in VA outcomes between the EVS and this study. In the EVS, 82.1% of the PPV group and 77.7% of the vitreous tap and injection group achieved 20/200 or better VA. 6 In this study, however, only 19 of 70 patients (27.1%) reached 20/400 or better VA. Other contributing factors to this difference include selection bias of patients with worse clinical appearance for PPV (nearly all the patients in this study had no view of the fundus on presentation), a higher incidence of more virulent organisms (e.g., Streptococcus sp.) in this study as compared with the EVS, and inclusion of etiologies that have been shown to have worse outcomes than postcataract endophthalmitis (e.g., posttrabeculectomy). 16, 17 This study reflects a different spectrum of patients than the EVS, as less than a third of the cases included in this series occurred in the postcataract setting. There may be a theoretical benefit to PPV in postintravitreal injection endophthalmitis patients, given both the higher incidence of monocularity due to coexisting pathology in the other eye (e.g., exudative age-related macular degeneration) and the higher incidence of more virulent organisms (such as Streptococcus sp.). 18 Despite the theoretical advantages of PPV in this cohort, subgroup analysis found no significant difference in presentation or final VA between the most common etiologies (postcataract, postintravitreal injection, and posttrabeculectomy) except that postintravitreal injection patients presented with better VA when compared with posttrabeculectomy patients. This difference may be due to a combination of baseline poorer acuity in eyes with advanced glaucoma and earlier presentation by patients after intravitreal injection given strict return cautions.
The average time from presentation to PPV in this study was 2.0 days. On subgroup analysis, there was no significant difference in VA outcomes between those patients undergoing surgery in the first 24 hours, the next 24 hours, or beyond 48 hours. A confounding factor in the analysis of surgical timing is that often the decision to perform PPV depends in part on corneal edema and other media factors that may impair the surgeon's ability to perform a safe and more complete PPV. One option in cases with poor view precluding biomicroscopic vitrectomy is the use of an endoscope. 19 Zhang et al 20 recently reported a series of 21 patients undergoing endoscopic-assisted immediate PPV for acute postcataract endophthalmitis. Of note, 2 of the 21 patients in that series experienced a retinal detachment within 2 weeks of initial surgery, possibly suggesting that endoscopic PPV still has its pitfalls in optimal viewing to ensure that no retinal breaks are inadvertently created and, if iatrogenic breaks occur that they are able to visualized and treated before completion of surgery. Also, in this study, among patients presenting with LP VA, while there was a significant improvement in VA from presentation to final visit, only 4 of 30 patients achieved 20/400 or better VA. Surgery within 24 hours did not result in significant improvement compared with surgery beyond 24 hours, although this included patients with all-cause endophthalmitis and not solely postcataract surgery. There were no significant differences seen between patients postcataract surgery versus other etiologies, although the sample sizes were likely too small to detect subtle differences.
In this series, the overall improvement in VA from presentation to final visit was reproduced on subgroup analysis of the 23-gauge cases but not the 25-gauge cases. Drawing conclusions related to gauge from either the previous or this study is impossible given the unequal and nonrandomized groups, the nonstandardization of technique, and the individual surgeon-making decision on gauge selection. However, there may be a theoretical advantage to a smaller platform than 20 gauge in safer vitreous gel removal, especially in light of a likely less than optimal view. A previously reported series reported superior VA outcomes and lower complications in those patients undergoing 25 gauge rather than 20-gauge PPV for endophthalmitis, although only 12 of the 70 included cases were 25 gauge. 21 Most of the culture-positive cases in the EVS were due to gram-positive coagulase-negative Staphylococcus sp. 6 In contrast, the most common organism identified in the current series was Streptococcus sp. These are virulent organisms generally associated with poorer outcomes; Kuriyan et al 17 reported the largest series of culture-positive Streptococcus endophthalmitis with 75% of patients having worse than 20/400 final VA and 25% patients undergoing evisceration or enucleation. Despite the preponderance of Streptococcus in this study, only one of the Streptococcus-positive cases underwent evisceration or enucleation; two patients in this study with positive cultures for a different organism (Candida albicans and Bacillus sp., respectively) underwent evisceration or enucleation. This may argue that while the overall visual outcomes in this study are poor, similar to other endophthalmitis studies, there may be an anatomically protective benefit to PPV that prevents either phthisis or panophthalmitis from developing and reduces the need for enucleation or evisceration.
The major limitation of this study is its retrospective nature, which lends to a selection bias of cases chosen to undergo PPV. While the use of multiple centers offers the advantage of a larger sample size and a broader geographic spread of causative organisms, there was no defined uniformity in surgical technique or surgeon approach to what constituted a therapeutic PPV (e.g., limited core vitrectomy vs. complete core vitrectomy). Timing of surgery and intravitreal antibiotic selection were at the discretion of the individual surgeon, and follow-up periods were not standardized. In addition, including multiple causative etiologies that have different typical clinical courses make it difficult to draw major conclusions from a retrospective consecutive case series. Despite these limitations, there is useful information to be garnered by analyzing cases undergoing PPV and real-world outcomes in the modern surgical era.
In conclusion, PPV for acute-onset infectious endophthalmitis was performed most frequently in postcataract surgery cases, and the most common causative organism was Streptococcus sp. infection. Although the overall visual outcomes were poor with less than onethird of patients achieving 20/400 vision, VA often improved from presentation to last follow-up visit, and the rate of globe loss was lower than may be expected given the virulence of organisms.
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